Starpharma Holdings Limited

ASX:SPL ISIN:AU000000SPL0

 Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. 
 
     

Sprache wählen

News

###

128,347 COMPANY PROFILE VIEWS

  • Diese Seite wurde besucht: (letzten 7 Tagen: 16) (letzten 30 Tagen: 115) (seit Veröffentlichung: 16845) 

Company Data

    Headquarters
  • Baker Building
    75 Commercial Road
    Melbourne VIC 3004
    AUSTRALIA
  • Telephone
  • +61 3 8532 2700  
  • Fax
  • +61 3 9510 5955  
  • Principal Sector
  • Gesundheit & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2000/09/28 
  • Homepage
  • www.starpharma.com

More News Results

  • 2024/11/01: Notification regarding unquoted securities - SPL*
  • 2024/10/31: Quarterly Activities/Appendix 4C Cash Flow Report*
  • 2024/10/29: Australian Microcap Conference Presentation*
  • 2024/10/28: Notice of Annual General Meeting/Proxy Form*
  • 2024/10/25: Application for quotation of securities - SPL*
  • 2024/10/24: Change of Director's Interest Notice - R Thomas*
  • 2024/10/18: SPL7013 Nasal Spray Australia Update*
  • 2024/10/03: Date of Annual General Meeting 2024*
  • 2024/10/03: Notification of cessation of securities - SPL*
  • 2024/09/16: Change of Director's Interest Notice - Dr Russell Basser*
*refer to company website